Online inquiry

IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7684MR)

This product GTTS-WQ7684MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD3E&MS4A1 gene. The antibody can be applied in B-cell malignancies research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens; Chimeric
RefSeq NM_000733.4; NM_021950.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 931
UniProt ID P07766; P11836
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ7684MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13906MR IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN-2176
GTTS-WQ14327MR IVTScrip™ mRNA-Anti-EGFL7, RG7414(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA RG7414
GTTS-WQ448MR IVTScrip™ mRNA-Anti-PDGFRA, 3G3(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA 3G3
GTTS-WQ15887MR IVTScrip™ mRNA-Anti-SLC34A2, XMT-1536(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA XMT-1536
GTTS-WQ6903MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ENB-0040
GTTS-WQ5953MR IVTScrip™ mRNA-Anti-IGHE, CL-2C(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CL-2C
GTTS-WQ8062MR IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA h2H12ec
GTTS-WQ14475MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA RO-7105705
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW